- Home
- XGN vs ATRA Comparison
XGN vs ATRA Comparison
Compare XGN & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XGN | ATRA |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.9M | 129.4M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | XGN | ATRA |
|---|---|---|
| Price | $6.00 | $17.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $13.67 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 258.8K | 74.4K |
| Earning Date | 11-04-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.97 |
| Revenue | $63,599,000.00 | ★ $151,930,000.00 |
| Revenue This Year | $21.76 | N/A |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | ★ N/A | $8.79 |
| Revenue Growth | 14.08 | ★ 51.27 |
| 52 Week Low | $2.67 | $5.01 |
| 52 Week High | $12.23 | $18.95 |
Technical Indicators
Market Signals| Indicator | XGN | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 61.83 |
| Support Level | $5.93 | $16.59 |
| Resistance Level | $6.34 | $18.30 |
| Average True Range (ATR) | 0.33 | 1.40 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 2.14 | 73.78 |
Price Performance
Historical ComparisonAbout XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).